Adage Capital Partners
DFTX

Adage Capital Partners’s Definium Therapeutics DFTX Stock Holding History

Adage Capital Partners’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47M Sell
1,000,000
-150,000
-13% -$3.71M 0.07% 294
2026
Q1 		$21.7M Hold
1,150,000
– – 0.03% 450
2025
Q4 		$15.4M Buy
1,150,000
+850,000
+283% +$10.5M 0.02% 567
2025
Q3 		$3.54M Buy
+300,000
New +$2.8M 0.01% 768

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Adage Capital Partners's DFTX Position: Q2 2026 in Review

Adage Capital Partners reduced its Definium Therapeutics (DFTX) stake by 13% in Q2 2026, selling an estimated $3.71M and leaving 1,000,000 shares worth $47M. The position accounts for 0.07% of the portfolio, ranked #294.

Adage Capital Partners first reported a position in DFTX in Q3 2025 and has held it in 4 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Adage Capital Partners held 1,000,000 shares of Definium Therapeutics worth $47M as of Q2 2026.
  • Adage Capital Partners sold 150,000 Definium Therapeutics shares in Q2 2026, an estimated $3.71M.
  • Definium Therapeutics made up 0.07% of Adage Capital Partners's portfolio in Q2 2026, its #294 holding.
  • Adage Capital Partners first reported a position in Definium Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.